doi: 10.1161/hc0302.103712
(Circulation. 2002;105:293.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Pivotal Role of a gp91phox-Containing NADPH Oxidase in Angiotensin II-Induced Cardiac Hypertrophy in Mice
From the Department of Cardiology, Guy’s, King’s and St Thomas’ School of Medicine, King’s College London, London, UK.
Correspondence to Prof A.M. Shah, Dept of Cardiology, GKT School of Medicine, Bessemer Road, London, SE5 9PJ, UK. E-mail ajay.shah{at}kcl.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Angiotensin II induces both cardiac and vascular smooth muscle (VSM) hypertrophy. Recent studies suggest a central role for a phagocyte-type NADPH oxidase in angiotensin II-induced VSM hypertrophy. The possible involvement of an NADPH oxidase in the development of cardiac hypertrophy has not been studied.
Methods and Results— Mice with targeted disruption of the NADPH oxidase subunit gp91phox (gp91phox-/-) and matched wild-type mice were subjected to subcutaneous angiotensin II infusion at a subpressor dose (0.3 mg/kg/day) for 2 weeks. Systolic blood pressure was unaltered by angiotensin II in either group. Angiotensin II significantly increased heart/body weight ratio, atrial natriuretic factor and ß-myosin heavy chain mRNA expression, myocyte area, and cardiac collagen content in wild-type but not gp91phox-/- mice. Angiotensin II treatment increased myocardial NADPH oxidase activity in wild-type but not gp91phox-/- mice.
Conclusions— A gp91phox-containing NADPH oxidase plays an important role in the development of angiotensin II-induced cardiac hypertrophy, independent of changes in blood pressure.
Key Words: hypertrophy • angiotensin • free radicals • myocardium
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin II (Ang II) plays an important role in the development and progression of cardiac hypertrophy.1 ACE inhibitors and Ang II receptor antagonists attenuate cardiac hypertrophy, both experimentally and in hypertensive patients.1 Multiple signaling pathways, eg, protein kinase C, mitogen-activated protein kinases (MAPKs), and others, are implicated in Ang II-induced cardiac hypertrophy.2 Recent studies suggest that Ang II mediates vascular smooth muscle (VSM) hypertrophy via production of intracellular reactive oxygen species (ROS), which activate crucial signaling cascades and have mitogenic effects.3,4 ROS production has also been implicated in cardiomyocyte hypertrophy.2,5
Phagocyte-type NADPH oxidases, a major source of ROS in cardiovascular cells, are implicated in Ang II-induced VSM hypertrophy4 and hypertension.6 These oxidases are expressed in endothelium,7,8 VSM,4 adventitial fibroblasts,9 and cardiomyocytes.10 In endothelium and fibroblasts, gp91phox is the major subunit responsible for enzyme activity, whereas in VSM, homologues such as nox1 may be more important.11 To date, the potential role of a gp91phox-containing NADPH oxidase in the development of cardiac hypertrophy has not been studied.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experiments were performed in accordance with the Guidance on the Operation of Animals (Scientific Procedures) Act, 1986 (UK) on male gp91phox-/- mice12 (The Jackson Laboratory, Maine) and matched wild-type controls with the same genetic background (C57BL/6J).
gp91phox mRNA expression was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) in left ventricle (LV) homogenate and isolated cardiomyocytes, using specific primers targeted to exon 3, which is disrupted in gp91phox-/- mice.12
NADPH Oxidase Activity
Isolated gp91phox-/- and control hearts (n
4/group) were perfused with Ang II (0.1 to 1 µmol/L) for 10 minutes and then snap-frozen. NADPH-dependent superoxide production was measured in LV homogenates using lucigenin (5 µmol/L)-enhanced chemiluminescence (NADPH 300 µmol/L; 100 µg protein; 37°C).4,7 Some experiments were performed in the presence of a cell-permeable O2- scavenger 4,5-dihydroxy-1,3-benzene-disulfonic acid (Tiron, 20 mmol/L), the flavoprotein inhibitor diphenyleneiodonium (DPI, 10 µmol/L), or a nitric oxide synthase inhibitor N
-Nitro-L-arginine methyl ester hydrochloride (L-NAME, 100 µmol/L).
Animal Model
Wild-type and gp91phox-/- mice (42±2 days old) were anesthetized by inhalation of 2% isoflurane, 98% oxygen. Osmotic minipumps (Alzet Model 1002; Alza Corp) containing either Ang II (infusion rate 0.3 mg/kg/day) or vehicle were implanted in the midscapular region. Blood pressure was monitored by tail cuff plethysmography (World Precision Instruments, UK) in conscious mice (9/group) following 3 training periods.
Assessment of Hypertrophy
Mice (n6/group) were euthanized and body and heart weights recorded. Additional hearts (n3/group) were fixed, sectioned (5 µm), and labeled with anti-laminin B2 antibody and counterstained with hematoxylin. Myocyte areas (>50 cells/section) were measured from transverse sections, by a blinded observer, using a digital image analyzer (Openlab 3.3.3, Improvision, UK). Collagen content was assessed by quantifying the blue pixel content from LV cryosections (6 µm) (n3/group) stained with Mason’s trichrome.
Atrial natriuretic factor (ANF) and ß-myosin heavy chain (ß-MHC) mRNA expression was measured by semiquantitative RT-PCR, with normalization to GAPDH expression.
Statistics
Data are presented as mean±SEM. Comparisons between groups were made by 1-way ANOVA, followed by Fischer’s least significance post hoc test or Student’s unpaired t test. A value of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline Characteristics
gp91phox mRNA was expressed in LV of wild-type but not gp91phox-/- mice (Figure 1A). Similar results were obtained using pure isolated cardiomyocytes (not shown). There was no significant difference in body weight among the 4 groups (in grams): sham wild-type, 25.0±0.7; Ang II-infused wild-type, 24.4±0.7; sham gp91phox-/-, 25.1±0.5; Ang II-infused gp91phox-/-, 24.4±0.6.
|
) and Ang II-infused (
) wild-type and gp91phox-/- mice. Right, Percentage change in heart/BWT ratio after Ang II infusion in wild-type and gp91phox-/- mice. *P<0.05; **P<0.01.
NADPH-Dependent Superoxide Production
Ang II treatment induced significant dose-dependent increases in NADPH oxidase activity in wild-type hearts but had no effect in gp91phox-/- hearts (Figure 1B). NADPH-dependent superoxide production was abolished by DPI and Tiron in all groups, but was unaffected by L-NAME (data not shown).
Blood Pressure
Basal systolic blood pressure was significantly lower in gp91phox-/- compared with wild-type mice (127±2.2 mm Hg versus 139±2.3 mm Hg). Ang II infusion (0.3 mg/kg/day) did not increase systolic blood pressure in either group (Figure 1C).
Cardiac Hypertrophic Response
Ang II infusion caused a significant increase in heart/body weight ratio in wild-type mice. This effect was substantially blunted and nonsignificant in gp91phox-/- mice (
8% increase versus 20% in wild-type) (Figure 1D). Expression of ANF and ß-MHC mRNA, 2 molecular markers of cardiac hypertrophy, was significantly increased after Ang II infusion in wild-type but not gp91phox-/- mice (Figures 2A and 2B). LV myocyte area was significantly increased in myocardial sections of wild-type mice treated with Ang II but not in corresponding gp91phox-/- animals (Figure 2C). Interstitial cardiac fibrosis was also significantly increased by Ang II infusion in wild-type mice, whereas no increase was observed in gp91phox-/- animals (Figure 2D).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The principal novel finding of this study is that a gp91phox-containing NADPH oxidase, present in cardiomyocytes, is centrally involved in the direct cardiac hypertrophic response to Ang II. Although Ang II infusion could theoretically also cause cardiac hypertrophy indirectly through changes in hemodynamic load (due to vasoconstriction), this possibility was excluded in the present study by the use of a subpressor Ang II dose. A marked attenuation of Ang II-induced cardiac hypertrophy in gp91phox-/- mice was demonstrated not only by morphometric assessment of heart/body weight ratio but also by measurements of myocyte area in LV sections and by mRNA expression of 2 standard molecular markers of cardiac hypertrophy, ANF and ß-MHC. Accumulation of interstitial collagen is an important feature of cardiac hypertrophy, contributing both to ventricular remodeling and diastolic dysfunction.13 AT1-overexpressing mice display a significant increase in collagen deposition in the myocardium.14 Interestingly, the marked increase in interstitial collagen content observed with Ang II infusion in wild-type mice was virtually abolished in gp91phox-/- mice. Taken together, these data provide the first convincing evidence that several aspects of Ang II-induced cardiac hypertrophy (ie, myocyte hypertrophy and interstitial fibrosis) are dependent on the presence of a gp91phox-containing NADPH oxidase. The relative contributions of different cell types (eg, cardiomyocytes, endothelial cells, fibroblasts) to this Ang II-induced, gp91phox-dependent hypertrophic response warrants further investigation.
In VSM, Ang II increases NADPH oxidase-dependent ROS production, which is thought to activate signaling pathways involved in the hypertrophic response.4 In the present study, we found that NADPH oxidase activity was increased by Ang II in wild-type hearts but that Ang II had no effect in gp91phox-/- animals. This finding is consistent with the hypothesis that ROS produced by a gp91phox-containing NADPH oxidase are involved in Ang II-mediated cardiac hypertrophy. The downstream pathways modulated by Ang II-stimulated ROS production in cardiac myocytes will require further study. In preliminary studies, we found no differences in the activation of extracellular signal regulated kinase (ERK1/2), c-Jun N-terminal kinase, or p38 MAPK between wild-type and gp91phox-/- mice treated with Ang II (data not shown).
An interesting observation in this study was that baseline systolic blood pressure was significantly lower in conscious gp91phox-/- mice compared with wild-type controls. Whereas gp91phox homologues, such as nox1, are thought to be more important than gp91phox itself for VSM function,11 the present data suggest that gp91phox is also involved in the regulation of VSM tone. Very recently, Wang et al15 also reported a reduced systolic blood pressure in gp91phox-/- mice. These authors also found that infusion of pressor doses of Ang II did increase blood pressure in gp91phox-/- mice. In the present study, it is unlikely that the lower blood pressure in gp91phox-/- mice accounted for the attenuated cardiac hypertrophic response to Ang II because we studied subpressor doses. Furthermore, in pilot studies, infusion of a pressor dose of Ang II failed to induce hypertrophy in these animals. The gp91phox-/- mice tended to have very slightly higher baseline heart/body weight ratios than wild-types (P=NS); however, this is unlikely to have limited hypertrophy because maximal hypertrophy in wild-type animals can exceed 100% (eg, after aortic banding; data not shown).
The present results add significantly to the growing body of evidence in support of an important role for NADPH oxidase in cardiovascular physiology and pathophysiology.16 Previous studies using the same mice with targeted disruption of gp91phox demonstrated an involvement of gp91phox in Ang II-induced vascular hypertrophy in vivo15 and in the regulation of vascular tone7 and basal systemic blood pressure.15 The present study is the first to suggest a direct functional role for a gp91phox-containing NADPH oxidase in the pathogenesis of Ang II-induced cardiac hypertrophy.
|
Acknowledgments |
|---|
This work was supported by the British Heart Foundation (BHF) Program Grant RG/98008 and the Joint Research Committee (JRC) of King’s Healthcare NHS Trust. J.B. is supported by a JRC PhD studentship. N.G. is supported by a BHF Junior Fellowship. A.M.S. holds the BHF Chair of Cardiology at King’s College London.
Received October 31, 2001; revision received December 4, 2001; accepted December 4, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 1999;xx 43: 838–849.
2. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998; 76: 725–746.[CrossRef][Medline] [Order article via Infotrieve]
3.
Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001; 81: 999–1030.
4.
Ushio-Fukai M, Zafari AM, Fukui T, et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;x 271: 23317–23321.
5.
Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-
and angiotensin II. Circulation. 1998; 98: 794–799.
6. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916–1923.[Medline] [Order article via Infotrieve]
7.
Gorlach A, Brandes RP, Nguyen K, et al. A gp91phox-containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000; 87: 26–32.
8.
Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20: 1903–1911.
9.
Pagano PJ, Chanock SJ, Siwik DA, et al. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension. 1998; 32: 331–337.
10.
Mohazzab-H KM, Kaminski PM, Wolin MS. Lactate and PO2 modulate superoxide anion production in bovine cardiac myocytes: potential role for NADH oxidase. Circulation. 1997; 96: 614–620.
11.
Lassegue B, Sorescu D, Szocs K, et al. Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001; 88: 888–894.
12. Pollock JD, Williams DA, Gifford MAC, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995; 9: 202–209.[CrossRef][Medline] [Order article via Infotrieve]
13.
Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997; 96: 4065–4082.
14.
Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000; 97: 931–936.
15.
Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001; 88: 947–953.
16.
Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.
This article has been cited by other articles:
 |
|
 |
|
  T. Yokota, S. Kinugawa, K. Hirabayashi, S. Matsushima, N. Inoue, Y. Ohta, S. Hamaguchi, M. A. Sobirin, T. Ono, T. Suga, et al. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1069 - H1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Widder, D. Fraccarollo, P. Galuppo, J. M. Hansen, D. P. Jones, G. Ertl, and J. Bauersachs Attenuation of Angiotensin II-Induced Vascular Dysfunction and Hypertension by Overexpression of Thioredoxin 2 Hypertension, August 1, 2009; 54(2): 338 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergamini, M. Cicoira, A. Rossi, and C. Vassanelli Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure Eur J Heart Fail, May 1, 2009; 11(5): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Zhang, A. N. D. Cat, C. Soukaseum, B. Escoubet, A. Cherfa, S. Messaoudi, C. Delcayre, J.-L. Samuel, and F. Jaisser Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling Hypertension, December 1, 2008; 52(6): 1060 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Papparella, G. Ceolotto, D. Montemurro, M. Antonello, S. Garbisa, G. Rossi, and A. Semplicini Green Tea Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Rats by Modulating Reactive Oxygen Species Production and the Src/Epidermal Growth Factor Receptor/Akt Signaling Pathway J. Nutr., September 1, 2008; 138(9): 1596 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Haque and D. S. A. Majid Reduced renal responses to nitric oxide synthase inhibition in mice lacking the gene for gp91phox subunit of NAD(P)H oxidase Am J Physiol Renal Physiol, September 1, 2008; 295(3): F758 - F764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Monassier, M.-A. Laplante, F. Jaffre, P. Bousquet, L. Maroteaux, and J. de Champlain Serotonin 5-HT2B Receptor Blockade Prevents Reactive Oxygen Species-Induced Cardiac Hypertrophy in Mice Hypertension, August 1, 2008; 52(2): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Anilkumar, R. Weber, M. Zhang, A. Brewer, and A. M. Shah Nox4 and Nox2 NADPH Oxidases Mediate Distinct Cellular Redox Signaling Responses to Agonist Stimulation Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1347 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Whaley-Connell, J. Habibi, S. A. Cooper, V. G. DeMarco, M. R. Hayden, C. S. Stump, D. Link, C. M. Ferrario, and J. R. Sowers Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E103 - E109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayashi, C. Yamashita, C. Matsumoto, C.-J. Kwak, K. Fujii, T. Hirata, M. Miyamura, T. Mori, A. Ukimura, Y. Okada, et al. Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2197 - H2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Starr, R. Graepel, J. Keeble, S. Schmidhuber, N. Clark, A. Grant, A. M. Shah, and S. D. Brain A reactive oxygen species-mediated component in neurogenic vasodilatation Cardiovasc Res, April 1, 2008; 78(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Zou, L. Yang, and S.-L. Yao Propofol Depresses Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro Experimental Biology and Medicine, February 1, 2008; 233(2): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Looi, D. J. Grieve, A. Siva, S. J. Walker, N. Anilkumar, A. C. Cave, M. Marber, M. J. Monaghan, and A. M. Shah Involvement of Nox2 NADPH Oxidase in Adverse Cardiac Remodeling After Myocardial Infarction Hypertension, February 1, 2008; 51(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sanchez, M. Escobar, Z. Pedrozo, P. Macho, R. Domenech, S. Hartel, C. Hidalgo, and P. Donoso Exercise and tachycardia increase NADPH oxidase and ryanodine receptor-2 activity: possible role in cardioprotection Cardiovasc Res, January 15, 2008; 77(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choi, T. L. Leto, L. Hunyady, K. J. Catt, Y. S. Bae, and S. G. Rhee Mechanism of Angiotensin II-induced Superoxide Production in Cells Reconstituted with Angiotensin Type 1 Receptor and the Components of NADPH Oxidase J. Biol. Chem., January 4, 2008; 283(1): 255 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ren, F. J. Raucci Jr., D. M. Browe, and C. M. Baumgarten Regulation of swelling-activated Cl- current by angiotensin II signalling and NADPH oxidase in rabbit ventricle Cardiovasc Res, January 1, 2008; 77(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Vendrov, Z. S. Hakim, N. R. Madamanchi, M. Rojas, C. Madamanchi, and M. S. Runge Atherosclerosis Is Attenuated by Limiting Superoxide Generation in Both Macrophages and Vessel Wall Cells Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Frank, C. Kuhn, M. van Eickels, D. Gehring, C. Hanselmann, S. Lippl, R. Will, H. A. Katus, and N. Frey Calsarcin-1 Protects Against Angiotensin-II Induced Cardiac Hypertrophy Circulation, November 27, 2007; 116(22): 2587 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-X. Zhang, X.-M. Lu, S. Kimura, and A. Nishiyama Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation Cardiovasc Res, November 1, 2007; 76(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Seddon, Y. H Looi, and A. M Shah Oxidative stress and redox signalling in cardiac hypertrophy and heart failure Heart, August 1, 2007; 93(8): 903 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Whaley-Connell, G. Govindarajan, J. Habibi, M. R. Hayden, S. A. Cooper, Y. Wei, L. Ma, M. Qazi, D. Link, P. R. Karuparthi, et al. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E355 - E363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Habibi, A. Whaley-Connell, M. A. Qazi, M. R. Hayden, S. A. Cooper, A. Tramontano, J. Thyfault, C. Stump, C. Ferrario, R. Muniyappa, et al. Rosuvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 Transgenic Rats Endocrinology, May 1, 2007; 148(5): 2181 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, I. Armando, L. D. Asico, C. Escano, X. Wang, Q. Lu, R. A. Felder, C. G. Schnackenberg, D. R. Sibley, G. M. Eisner, et al. The elevated blood pressure of human GRK4{gamma} A142V transgenic mice is not associated with increased ROS production Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2083 - H2092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Bendall, R. Rinze, D. Adlam, A. L. Tatham, J. de Bono, and K. M. Channon Endothelial Nox2 Overexpression Potentiates Vascular Oxidative Stress and Hemodynamic Response to Angiotensin II: Studies in Endothelial-Targeted Nox2 Transgenic Mice Circ. Res., April 13, 2007; 100(7): 1016 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto and D. A. Kass Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling Hypertension, February 1, 2007; 49(2): 241 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Zimmet and J. M. Hare Nitroso-Redox Interactions in the Cardiovascular System Circulation, October 3, 2006; 114(14): 1531 - 1544. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Pillai, M. Gupta, S. B. Rajamohan, R. Lang, J. Raman, and M. P. Gupta Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1545 - H1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Hingtgen, X. Tian, J. Yang, S. M. Dunlay, A. S. Peek, Y. Wu, R. V. Sharma, J. F. Engelhardt, and R. L. Davisson Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy Physiol Genomics, September 14, 2006; 26(3): 180 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Grote, M. Ortmann, G. Salguero, C. Doerries, U. Landmesser, M. Luchtefeld, R. P. Brandes, W. Gwinner, T. Tschernig, E.-G. Brabant, et al. Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation Cardiovasc Res, August 1, 2006; 71(3): 596 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Custodis, M. Eberl, H. Kilter, M. Bohm, and U. Laufs Association of RhoGDI{alpha} with Rac1 GTPase mediates free radical production during myocardial hypertrophy Cardiovasc Res, July 15, 2006; 71(2): 342 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J, July 1, 2006; 20(9): 1546 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Cameron, T. J. Mocatta, A. P. Pilbrow, C. M. Frampton, R. W. Troughton, A. M. Richards, and C. C. Winterbourn Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure Hypertension, June 1, 2006; 47(6): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Satoh, H. Ogita, K. Takeshita, Y. Mukai, D. J. Kwiatkowski, and J. K. Liao Requirement of Rac1 in the development of cardiac hypertrophy PNAS, May 9, 2006; 103(19): 7432 - 7437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, A. L. Kho, N. Anilkumar, R. Chibber, P. J. Pagano, A. M. Shah, and A. C. Cave Glycated Proteins Stimulate Reactive Oxygen Species Production in Cardiac Myocytes: Involvement of Nox2 (gp91phox)-Containing NADPH Oxidase Circulation, March 7, 2006; 113(9): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Grieve, J. A. Byrne, A. Siva, J. Layland, S. Johar, A. C. Cave, and A. M. Shah Involvement of the Nicotinamide Adenosine Dinucleotide Phosphate Oxidase Isoform Nox2 in Cardiac Contractile Dysfunction Occurring in Response to Pressure Overload J. Am. Coll. Cardiol., February 21, 2006; 47(4): 817 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Arimoto, Y. Takeishi, H. Takahashi, T. Shishido, T. Niizeki, Y. Koyama, R. Shiga, N. Nozaki, O. Nakajima, K. Nishimaru, et al. Cardiac-Specific Overexpression of Diacylglycerol Kinase {zeta} Prevents Gq Protein-Coupled Receptor Agonist-Induced Cardiac Hypertrophy in Transgenic Mice Circulation, January 3, 2006; 113(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sabri and P. A. Lucchesi ANG II and cardiac myocyte contractility: p38 is not stressed out! Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H72 - H73. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cave, D. Grieve, S. Johar, M. Zhang, and A. M Shah NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology Phil Trans R Soc B, December 29, 2005; 360(1464): 2327 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rocic and P. A. Lucchesi NAD(P)H Oxidases and TGF-{beta}-Induced Cardiac Fibroblast Differentiation: Nox-4 Gets Smad Circ. Res., October 28, 2005; 97(9): 850 - 852. [Full Text] [PDF]
|
|
|
|
|
|
I. Cucoranu, R. Clempus, A. Dikalova, P. J. Phelan, S. Ariyan, S. Dikalov, and D. Sorescu NAD(P)H Oxidase 4 Mediates Transforming Growth Factor-{beta}1-Induced Differentiation of Cardiac Fibroblasts Into Myofibroblasts Circ. Res., October 28, 2005; 97(9): 900 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hool, C. A. Di Maria, H. M. Viola, and P. G. Arthur Role of NAD(P)H oxidase in the regulation of cardiac L-type Ca2+ channel function during acute hypoxia Cardiovasc Res, September 1, 2005; 67(4): 624 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinugawa, J. Zhang, E. Messina, E. Walsh, H. Huang, P. M. Kaminski, M. S. Wolin, and T. H. Hintze gp91phox-containing NAD(P)H oxidase mediates attenuation of nitric oxide-dependent control of myocardial oxygen consumption by ANG II Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H862 - H867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wu, M.-A. Laplante, and J. de Champlain Cyclooxygenase-2 Inhibitors Attenuate Angiotensin II-Induced Oxidative Stress, Hypertension, and Cardiac Hypertrophy in Rats Hypertension, June 1, 2005; 45(6): 1139 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kimura, G.-X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y.-Y. Fan, M. Rahman, T. Suzuki, H. Maeta, and Y. Abe Role of NAD(P)H Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Cardioprotection of Ischemic Reperfusion Injury by Angiotensin II Hypertension, May 1, 2005; 45(5): 860 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Peng, X. Lu, and Q. Feng Pivotal Role of gp91phox-Containing NADH Oxidase in Lipopolysaccharide-Induced Tumor Necrosis Factor-{alpha} Expression and Myocardial Depression Circulation, April 5, 2005; 111(13): 1637 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Touyz, C. Mercure, Y. He, D. Javeshghani, G. Yao, G. E. Callera, A. Yogi, N. Lochard, and T. L. Reudelhuber Angiotensin II-Dependent Chronic Hypertension and Cardiac Hypertrophy Are Unaffected by gp91phox-Containing NADPH Oxidase Hypertension, April 1, 2005; 45(4): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Anning, B. Coles, A. Bermudez-Fajardo, P. E.M. Martin, B. S. Levison, S. L. Hazen, C. D. Funk, H. Kuhn, and V. B. O'Donnell Elevated Endothelial Nitric Oxide Bioactivity and Resistance to Angiotensin-Dependent Hypertension in 12/15-Lipoxygenase Knockout Mice Am. J. Pathol., March 1, 2005; 166(3): 653 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Quinn and K. A. Gauss Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases J. Leukoc. Biol., October 1, 2004; 76(4): 760 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Wheatcroft, A. M. Shah, J.-M. Li, E. Duncan, B. T. Noronha, P. A. Crossey, and M. T. Kearney Preserved Glucoregulation but Attenuation of the Vascular Actions of Insulin in Mice Heterozygous for Knockout of the Insulin Receptor Diabetes, October 1, 2004; 53(10): 2645 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Browe and C. M. Baumgarten Angiotensin II (AT1) Receptors and NADPH Oxidase Regulate Cl- Current Elicited by {beta}1 Integrin Stretch in Rabbit Ventricular Myocytes J. Gen. Physiol., August 30, 2004; 124(3): 273 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-M. Hu, Y.-H. Chen, M.-T. Chiang, and L.-Y. Chau Heme Oxygenase-1 Inhibits Angiotensin II-Induced Cardiac Hypertrophy In Vitro and In Vivo Circulation, July 20, 2004; 110(3): 309 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K K Griendling Novel NAD(P)H oxidases in the cardiovascular system Heart, May 1, 2004; 90(5): 491 - 493. [Full Text] [PDF]
|
|
|
|
|
|
W. Nadruz Jr, V. J. Lagosta, H. Moreno Jr, O. R. Coelho, and K. G. Franchini Simvastatin Prevents Load-Induced Protein Tyrosine Nitration in Overloaded Hearts Hypertension, May 1, 2004; 43(5): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Li, S. Wheatcroft, L. M. Fan, M. T. Kearney, and A. M. Shah Opposing Roles of p47phox in Basal Versus Angiotensin II-Stimulated Alterations in Vascular O2- Production, Vascular Tone, and Mitogen-Activated Protein Kinase Activation Circulation, March 16, 2004; 109(10): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maytin, D. A. Siwik, M. Ito, L. Xiao, D. B. Sawyer, R. Liao, and W. S. Colucci Pressure Overload-Induced Myocardial Hypertrophy in Mice Does Not Require gp91phox Circulation, March 9, 2004; 109(9): 1168 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Shah and C. Heymes NADPH oxidose in the failing human heart: Reply J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2171 - 2172. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Grieve and A. M Shah Oxidative stress in heart failure: More than just damage Eur. Heart J., December 2, 2003; 24(24): 2161 - 2163. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Byrne,*, D. J. Grieve, J. K. Bendall, J.-M. Li, C. Gove, J. D. Lambeth, A. C. Cave, and A. M. Shah Contrasting Roles of NADPH Oxidase Isoforms in Pressure-Overload Versus Angiotensin II-Induced Cardiac Hypertrophy Circ. Res., October 31, 2003; 93(9): 802 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Higashi, H. Shimokawa, T. Hattori, J. Hiroki, Y. Mukai, K. Morikawa, T. Ichiki, S. Takahashi, and A. Takeshita Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II-Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System Circ. Res., October 17, 2003; 93(8): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gregg, F. M. Rauscher, and P. J. Goldschmidt-Clermont Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch Am J Physiol Cell Physiol, October 1, 2003; 285(4): C723 - C734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Grohe The cardiac cocaine connection Cardiovasc Res, October 1, 2003; 59(4): 805 - 806. [Full Text] [PDF]
|
|
|
|
|
|
F. Moritz, C. Monteil, M. Isabelle, F. Bauer, S. Renet, P. Mulder, V. Richard, and C. Thuillez Role of reactive oxygen species in cocaine-induced cardiac dysfunction Cardiovasc Res, October 1, 2003; 59(4): 834 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maack, T. Kartes, H. Kilter, H.-J. Schafers, G. Nickenig, M. Bohm, and U. Laufs Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment Circulation, September 30, 2003; 108(13): 1567 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M. Shah ROS Generation by Nonphagocytic NADPH Oxidase: Potential Relevance in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S221 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heymes, J. K. Bendall, P. Ratajczak, A. C. Cave, J.-L. Samuel, G. Hasenfuss, and A. M. Shah Increased myocardial NADPH oxidase activity in human heart failure J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Warnholtz and T. Munzel The failing human heart: Another battlefield for the NAD(P)H oxidase? J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2172 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Brandes A Radical Adventure: The Quest for Specific Functions and Inhibitors of Vascular NAPDH Oxidases Circ. Res., April 4, 2003; 92(6): 583 - 585. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Li and A. M. Shah Mechanism of Endothelial Cell NADPH Oxidase Activation by Angiotensin II. ROLE OF THE p47phox SUBUNIT J. Biol. Chem., March 28, 2003; 278(14): 12094 - 12100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ye, N. S. Metreveli, J. Ren, and P. N. Epstein Metallothionein Prevents Diabetes-Induced Deficits in Cardiomyocytes by Inhibiting Reactive Oxygen Species Production Diabetes, March 1, 2003; 52(3): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A J Krijnen, C Meischl, C E Hack, C J L M Meijer, C A Visser, D Roos, and H W M Niessen Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction J. Clin. Pathol., March 1, 2003; 56(3): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||